Thus, TGF-β is overexpressed in the majority of advanced ccRCC tumors, is involved in the regulation of biomarkers implicated in drug resistance, increased tumor angiogenesis, and mitochondrial lipid metabolism, and is shown to be a target of selenium. Here, TGFB1 is linked to neoplasm.